Cargando…

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment

Detalles Bibliográficos
Autores principales:	Jie, Hyun-Bae, Li, Jing, Srivastava, Raghvendra, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991356/ http://dx.doi.org/10.1186/2051-1426-1-S1-P190

Ejemplares similares

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

Highly expression of Tim-3 on HIV-specific T cells associated with disease progression and T-cell exhaustion in HIV-1 infected Chinese
por: Liu, Z, et al.
Publicado: (2012)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

T-cell exhaustion in the tumor microenvironment
por: Jiang, Y, et al.
Publicado: (2015)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Remodulation of the tumor microenvironment by regulatory T cells
por: Liu, Chang, et al.
Publicado: (2015)

Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment
por: McRitchie, Bayley R., et al.
Publicado: (2022)

TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection
por: Jayaraman, Pushpa, et al.
Publicado: (2016)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

Tim-3-mediated signaling in NK cells may be modulated by increased Galectin-9 expression in HIV-1 infection
por: Jost, S, et al.
Publicado: (2012)

Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment
por: Banerjee, Hridesh, et al.
Publicado: (2021)

NK cell exhaustion in the tumor microenvironment
por: Jia, Hao, et al.
Publicado: (2023)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2010)

Characterization of age‐associated exhausted CD8(+) T cells defined by increased expression of Tim‐3 and PD‐1
por: Lee, Kyoo‐A, et al.
Publicado: (2016)

P20. Lack of T cell exhaustion in acute myeloid leukaemia
por: Schnorfeil, FM, et al.
Publicado: (2014)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Dual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment
por: Kosmides, Alyssa K, et al.
Publicado: (2014)

Genome editing of tumor specific T cells for sustained functionality in a suppressive tumor microenvironment
por: Pedersen, Sara R, et al.
Publicado: (2015)

Tim-3 Negatively Regulates Cytotoxicity in Exhausted CD8(+) T Cells in HIV Infection
por: Sakhdari, Ali, et al.
Publicado: (2012)

Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3
por: Weber, Jeffrey K., et al.
Publicado: (2017)

Muci specific IGE to modify myeloid derived cells of the tumor microenvironment
por: Mollick, J, et al.
Publicado: (2013)

Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment
por: Subbiah, Vivek, et al.
Publicado: (2014)

Programming the lymph node microenvironment to enhance anti-tumor T cell immunity in neuroblastoma
por: Gammon, Joshua M, et al.
Publicado: (2015)

Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC
por: Ji, Jie, et al.
Publicado: (2018)

Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
por: Antonios, Joseph, et al.
Publicado: (2015)

TIM‐3 as a potential exhaustion marker in CD4(+) T cells of COVID‐19 patients
por: Modabber, Zahra, et al.
Publicado: (2021)

Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion
por: Zhu, Chen, et al.
Publicado: (2021)

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control
por: Williams, Jason B, et al.
Publicado: (2015)

IL-15 is an inflammatory mediator in the tumor microenvironment
por: Anthony, Scott M, et al.
Publicado: (2015)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection
por: Nebbia, Gaia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j1kf4t26nfg9nml81et1fhpkqn